Rajeev Krishnadas

Rajeev Krishnadas

Auto-generated profile, based on publicly available information

Rajeev Krishnadas

University of Cambridge

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2012 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
RKRajeev Krishnadas
Rajeev Krishnadas
JCJonathan Cavanagh
Jonathan Cavanagh
Major depressive disorder (MDD) is associated with significant morbidity and mortality. Findings from preclinical and clinical studies suggest that psychiatric illnesses, particularly MDD, are associated with inflammatory processes. While it is unlikely that MDD is a primary ‘inflammatory’ disorder, there is now evidence to suggest that inflammation may play a subtle role in the pathophysiology of MDD. Most of the evidence that links inflammation to MDD comes from three observations: (a) one-third of those with major depression show elevated peripheral inflammatory biomarkers, even in the absence of a medical illness; (b) inflammatory illnesses are associated with greater rates of MDD; and (c) patients treated with cytokines are at greater risk of developing major depressive illness. We now know that the brain is not an immune privileged organ. Inflammatory mediators have been found to affect various substrates thought to be important in the aetiopathogenesis of MDD, including altered monoamine and glutamate neurotransmission, glucocorticoid receptor resistance and adult hippocampal neurogenesis. At a higher level, inflammation is thought to affect brain signalling patterns, cognition and the production of a constellation of symptoms, termed ‘sickness behaviour’. Inflammation may therefore play a role in the aetiology of depression, at least in a ‘cohort’ of vulnerable individuals. Inflammation may not only act as a precipitating factor that pushes a person into depression but also a perpetuating factor that may pose an obstacle to recovery. More importantly, inflammatory markers may aid in the diagnosis and prediction of treatment response, leading to the possibility of tailored treatments, thereby allowing stratification of what remains a heterogenous disorder.

14 November 2017 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SLS P Leighton
S P Leighton
LNL Nerurkar
L Nerurkar
RKR Krishnadas
R Krishnadas
CJC Johnman
C Johnman
GGG J Graham
G J Graham
JCJ Cavanagh
J Cavanagh
Inflammatory illness is associated with depression. Preclinical work has shown that chemokines are linked with peripheral–central crosstalk and may be important in mediating depressive behaviours. We sought to establish what evidence exists that differences in blood or cerebrospinal fluid chemokine concentration discriminate between individuals with depression and those without. Following PRISMA guidelines, we systematically searched Embase, PsycINFO and Medline databases. We included participants with physical illness for subgroup analysis, and excluded participants with comorbid psychiatric diagnoses. Seventy-three studies met the inclusion criteria for the meta-analysis. Individuals with depression had higher levels of blood CXCL4 and CXCL7 and lower levels of blood CCL4. Sensitivity analysis of studies with only physically healthy participants identified higher blood levels of CCL2, CCL3, CCL11, CXCL7 and CXCL8 and lower blood levels of CCL4. All other chemokines examined did not reveal significant differences (blood CCL5, CCL7, CXCL9, CXCL10 and cerebrospinal fluid CXCL8 and CXCL10). Analysis of the clinical utility of the effect size of plasma CXCL8 in healthy individuals found a negative predictive value 93.5%, given the population prevalence of depression of 10%. Overall, our meta-analysis finds evidence linking abnormalities of blood chemokines with depression in humans. Furthermore, we have demonstrated the possibility of classifying individuals with depression based on their inflammatory biomarker profile. Future research should explore putative mechanisms underlying this association, attempt to replicate existing findings in larger populations and aim to develop new diagnostic and therapeutic strategies.

1 April 2015 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
SISarina J. Iwabuchi
Sarina J. Iwabuchi
RKRajeev Krishnadas
Rajeev Krishnadas
CLChunbo Li
Chunbo Li
DADorothee P. Auer
Dorothee P. Auer
Joaquim RaduàJoaquim Raduà
Joaquim Raduà
LENA PALANIYAPPANLENA PALANIYAPPAN
LENA PALANIYAPPAN

1 January 2019 in Biological Psychiatry
Verified
Journal Article
Closed access
KSKaustubh Supekar
Kaustubh Supekar
WCWeidong Cai
Weidong Cai
RKRajeev Krishnadas
Rajeev Krishnadas
LENA PALANIYAPPANLENA PALANIYAPPAN
LENA PALANIYAPPAN
VMVinod Menon
Vinod Menon

23 July 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JCJim Crabb
Jim Crabb
RSRobert C Stewart
Robert C Stewart
DKDemoubly Kokota
Demoubly Kokota
NMNeil Masson
Neil Masson
SCSylvester Chabunya
Sylvester Chabunya
RKRajeev Krishnadas
Rajeev Krishnadas
Stigma and discrimination associated with mental illness are strongly linked to suffering, disability and poverty. In order to protect the rights of those with mental disorders and to sensitively develop services, it is vital to gain a more accurate understanding of the frequency and nature of stigma against people with mental illness. Little research about this issue has been conducted in Sub- Saharan Africa. Our study aimed to describe levels of stigma in Malawi.

1 October 2012 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
RKRajeev Krishnadas
Rajeev Krishnadas
SJSameer Jauhar
Sameer Jauhar
STSusan Telfer
Susan Telfer
SSSomashekara Shivashankar
Somashekara Shivashankar
RMRobin G. McCreadie
Robin G. McCreadie
Background